中华中医药学刊

止血明目方联合抗VEGF治疗糖尿病视网膜病变Ⅴ期合并玻璃体积血的临床研究

PDF下载

苑志峰 , 张瑞红 , 王鑫

中华中医药学刊 | 国家项目点击 2026,44(8): 129-133

收起

中华中医药学刊 |国家项目点击 2026 , 44 (8) : 129 -133

止血明目方联合抗VEGF治疗糖尿病视网膜病变Ⅴ期合并玻璃体积血的临床研究

全屏

[Author(id=1319291442950943527, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1319291442049168160, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1319291443030635305, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1319291442049168160, authorId=1319291442950943527, language=EN, stringName=Zhifeng YUAN, firstName=Zhifeng, middleName=null, lastName=YUAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Hebei Eye Hospital, Hebei Eye Research Institute, Xingtai 054001, Hebei, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1319291443097744170, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1319291442049168160, authorId=1319291442950943527, language=CN, stringName=苑志峰, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=河北省眼科医院，河北眼科研究所，河北　邢台　054001, bio={"content":"

苑志峰（1980-），男，河北邢台人，主治医师，硕士，研究方向：眼底病。

"}, bioImg=null, bioContent=

苑志峰（1980-），男，河北邢台人，主治医师，硕士，研究方向：眼底病。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1319291442846085923, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1319291442049168160, xref=null, ext=[AuthorCompanyExt(id=1319291442854474532, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1319291442049168160, companyId=1319291442846085923, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Hebei Eye Hospital, Hebei Eye Research Institute, Xingtai 054001, Hebei, China), AuthorCompanyExt(id=1319291442871251749, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1319291442049168160, companyId=1319291442846085923, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=河北省眼科医院，河北眼科研究所，河北　邢台　054001)])]), Author(id=1319291443160658732, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1319291442049168160, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1319291443248739118, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1319291442049168160, authorId=1319291443160658732, language=EN, stringName=Ruihong ZHANG, firstName=Ruihong, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Hebei Eye Hospital, Hebei Eye Research Institute, Xingtai 054001, Hebei, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1319291443328430895, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1319291442049168160, authorId=1319291443160658732, language=CN, stringName=张瑞红, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=河北省眼科医院，河北眼科研究所，河北　邢台　054001, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1319291442846085923, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1319291442049168160, xref=null, ext=[AuthorCompanyExt(id=1319291442854474532, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1319291442049168160, companyId=1319291442846085923, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Hebei Eye Hospital, Hebei Eye Research Institute, Xingtai 054001, Hebei, China), AuthorCompanyExt(id=1319291442871251749, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1319291442049168160, companyId=1319291442846085923, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=河北省眼科医院，河北眼科研究所，河北　邢台　054001)])]), Author(id=1319291443391345457, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1319291442049168160, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1319291443475231539, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1319291442049168160, authorId=1319291443391345457, language=EN, stringName=Xin WANG, firstName=Xin, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Hebei Eye Hospital, Hebei Eye Research Institute, Xingtai 054001, Hebei, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1319291443538146100, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1319291442049168160, authorId=1319291443391345457, language=CN, stringName=王鑫, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=河北省眼科医院，河北眼科研究所，河北　邢台　054001, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1319291442846085923, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1319291442049168160, xref=null, ext=[AuthorCompanyExt(id=1319291442854474532, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1319291442049168160, companyId=1319291442846085923, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Hebei Eye Hospital, Hebei Eye Research Institute, Xingtai 054001, Hebei, China), AuthorCompanyExt(id=1319291442871251749, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1319291442049168160, companyId=1319291442846085923, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=河北省眼科医院，河北眼科研究所，河北　邢台　054001)])])]

苑志峰, 张瑞红, 王鑫

作者信息

河北省眼科医院，河北眼科研究所，河北　邢台　054001

作者简介:

苑志峰（1980-），男，河北邢台人，主治医师，硕士，研究方向：眼底病。

Efficacy of Zhixue Mingmu Formula (止血明目方) Combined with Anti-VEGF Therapy in Stage V Diabetic Retinopathy Complicated by Vitreous Hemorrhage

Zhifeng YUAN, Ruihong ZHANG, Xin WANG

Affiliations

Hebei Eye Hospital, Hebei Eye Research Institute, Xingtai 054001, Hebei, China

出版时间: 2026-08-10 doi: 10.13193/j.issn.1673-7717.2026.08.027

文章导航

摘要

收起

目的

深入探究止血明目方与康柏西普眼用注射液、羟苯磺酸钙胶囊联合应用治疗糖尿病视网膜病变Ⅴ期伴有玻璃体积血患者的临床疗效。

方法

2022年1月—2024年12月河北省眼科医院收治的100例糖尿病视网膜病变（Diabetic retinopathy，DR）Ⅴ期并伴有玻璃体积血（Vitreous hemorrhage，VH）早期患者，随机分为两组，每组50例，分别为观察组和对照组。对照组接受康柏西普眼用注射液和羟苯磺酸钙胶囊治疗，观察组在对照组的治疗基础上额外使用止血明目方。所有患者均遵循低盐低脂的糖尿病饮食，进行适度的运动，并使用常规降血糖药物。治疗过程持续8周，在此期间，记录了患者治疗前后的相关观察指标，以评估这两种治疗方案的临床效果。观察指标：对比两组治疗效果、中医症状积分、最佳矫正视力（Best corrected visual acuity，BCVA）、眼压、玻璃体积血吸收情况、眼底检查情况及缺氧诱导因子-1（Hypoxia-inducible factor-1，HIF-1）、血管内皮生长因子（Vascular endothelial growth factor，VEGF）水平变化。

结果

观察组治疗总有效率为94.0%（47/50），远高于对照组的78.0%（39/50），组间比较差异有统计学意义（P<0.05）；治疗后观察组中医症状积分、眼压降低、患眼BCVA、玻璃体积血吸收情况好于对照组（P<0.05）；治疗后观察组视野灰度值、血管瘤、出血斑、黄斑厚度低于对照组（P<0.05）；治疗后两组HIF-1、VEGF水平均降低，且观察组上述指标水平低于对照组（P<0.05）。

结论

采用止血明目方联合康柏西普眼用注射液及羟苯磺酸钙胶囊治疗Ⅴ期糖尿病视网膜病变并发玻璃体积血患者，结果显示该方案能显著促进视力恢复及玻璃体积血吸收，有助于维持眼压稳定性，并有效降低HIF-1及VEGF的表达水平。

关键词

糖尿病视网膜病变 / 玻璃体积血 / 止血明目方 / VEGF治疗 / 中西医结合治疗 / 视网膜微循环

Abstract

收起

Objective

To investigate the clinical efficacy of combining Zhixue Mingmu Formula (止血明目方) with Conbercept Ophthalmic Injection and Calcium Dobesilate Capsules in treating the patients with stage V diabetic retinopathy (DR) accompanied by vitreous hemorrhage (VH).

Methods

From January 2022 to December 2024, 100 early-stage patients diagnosed with stage V DR and VH at Hebei Provincial Eye Hospital were recruited. They were randomly divided into the observation group and the control group (50 patients in each). The control group received Conbercept Ophthalmic Injection and Calcium Dobesilate Capsules, while the observation group additionally received Zhixue Mingmu Formula. All patients adhered to a low-salt, low-fat diabetic diet, engaged in moderate exercise, and maintained conventional hypoglycemic therapy. The treatment duration was 8 weeks. Relevant clinical parameters were recorded before and after treatment to evaluate the clinical effects of these two therapeutic regimens. The therapeutic effects, TCM syndrome scores, best-corrected visual acuity, intraocular pressure, vitreous hemorrhage absorption, fundus examination findings and changes in serum levels of hypoxia-inducible factor-1 (HIF-1) and vascular endothelial growth factor (VEGF) between the two groups were compared.

Results

The total effective rate of the observation group was 94.0% (47/50), which was much higher than 78.0% (39/50) of the control group, and the difference between the groups was significant (P<0.05). After treatment, the observation group showed better scores in TCM symptoms, decreased intraocular pressure, best corrected visual acuity of the affected eye, and better absorption of vitreous hemorrhage compared to the control group (P<0.05). After treatment, the observation group had lower visual field gray values, vascular tumors, bleeding spots and macular thickness than the control group (P<0.05). After treatment, the levels of HIF-1 and VEGF in both groups decreased, and the levels of these indicators in the observation group were lower than those in the control group (P<0.05).

Conclusion

The combination regimen of Zhixue Mingmu Formula with anti-VEGF therapy effectively promotes visual rehabilitation and vitreous hemorrhage resolution, maintains the stability of intraocular pressure and downregulates the levels of HIF-1α and VEGF in the stage V DR patients.

Key words

diabetic retinopathy / vitreous hemorrhage / Zhixue Mingmu Formula (止血明目方) / anti-VEGF therapy / integrated traditional Chinese-Western therapy / retinal microcirculation

引用本文

苑志峰, 张瑞红, 王鑫. 止血明目方联合抗VEGF治疗糖尿病视网膜病变Ⅴ期合并玻璃体积血的临床研究. 中华中医药学刊, 2026 , 44 (8) : 129 -133 . DOI: 10.13193/j.issn.1673-7717.2026.08.027

Zhifeng YUAN, Ruihong ZHANG, Xin WANG. Efficacy of Zhixue Mingmu Formula (止血明目方) Combined with Anti-VEGF Therapy in Stage V Diabetic Retinopathy Complicated by Vitreous Hemorrhage[J]. Chinese Archives of Traditional Chinese Medicine, 2026 , 44 (8) : 129 -133 . DOI: 10.13193/j.issn.1673-7717.2026.08.027

基金

收起

国家重点研发计划项目(2019YFC1710201)
河北省卫生健康委科研基金项目(20191053)
河北省邢台市科学技术局项目(2023ZC174)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

彭晓莉, 唐阳明, 陈亦霞. 加味地黄丸联合抗VEGF治疗增殖性糖尿病视网膜病变的疗效及对眼内炎症因子影响[J]. 中华中医药学刊, 2025, 43(6): 225-229.

[2]

吴静, 张迁. 止血散瘀明目汤联合全视网膜激光光凝对糖尿病视网膜病变患者视力、黄斑厚度及血清脂联素水平的影响[J]. 广州中医药大学学报, 2024, 41(5): 1207-1212.

[3]

郭心仪, 黄栊瑢, 郭永红, 等. 利用LC-MS/MS和网络药理学探讨丹黄明目汤对糖尿病视网膜病变的潜在治疗作用[J]. 湖南中医药大学学报, 2024, 44(12): 2257-2266.

[4]

吴丹. 杞菊地黄汤联合通窍明目针法治疗糖尿病视网膜病变的临床观察[J]. 中国中医药现代远程教育, 2024, 22(4): 118-120.

[5]

毛盼, 杨胜家, 周新. 丹黄明目汤在糖尿病视网膜病变患者术后的应用效果[J]. 河南医学研究, 2024, 33(11): 2060-2063.

[6]

中华医学会眼科学会眼底病学组. 我国糖尿病视网膜病变临床诊疗指南(2014年)[J]. 中华眼科杂志, 2014, 50(11): 851-865.

[7]

中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中国实用内科杂志, 2018, 38(4): 292-344.

[8]

段俊国, 金明, 接传红, 等. 糖尿病视网膜病变中医诊疗标准[J]. 世界中西医结合杂志, 2011, 6(7): 632-637.

[9]

中华人民共和国卫生部. 中药新药临床研究指导原则[M]. 北京: 人民卫生出版社, 2002: 344.

[10]

张达臻, 杭丹丹, 娄赟. 益气养阴明目方联合丹参注射液治疗非增生性糖尿病视网膜病变患者的效果[J]. 中国民康医学, 2024, 36(1): 120-123.

[11]

宋艳, 王予, 杨丽, 等. 石斛明目丸联合甲钴胺治疗糖尿病视网膜病变的效果分析[J]. 中国实用医刊, 2024, 51(21): 118-120.

[12]

REUTRAKUL S, PARK J C, MCANANY J J, et al. Dysregulated 24 h melatonin secretion associated with intrinsically photosensitive retinal ganglion cell function in diabetic retinopathy: a cross-sectional study[J]. Diabetologia, 2024, 67(6): 1114-1121.

[13]

RAMAN R, KUMAR S. Patient-centered perspectives in diabetic retinopathy care: phenomenology and practice[J]. Evid Based Nurs, 2024, 27(2): 62.

[14]

MAZLOUM KHORASANI Z, HOSSEINI S M, SAFAEI M, et al. The role of serum level of irisin in diabetic retinopathy[J]. Int J Diabetes Dev Ctries, 2024, 44(2): 350-355.

[15]

IGWEOKPALA S, SULE N O, DOUROS A, et al. Incretin-based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: a systematic review and meta-analysis of observational studies[J]. Diabetes Obesity Metabolism, 2024, 26(2): 721-731.

[16]

徐凌, 罗曰栋, 刘金仁. 活血养阴明目方对非增生性糖尿病视网膜病变的影响[J]. 光明中医, 2024, 39(12): 2406-2409.

[17]

诸安蓉, 彭华华, 叶程程. 明目热奄包联合揿针治疗糖尿病视网膜病变疗效观察及对眼部血管、血流的影响[J]. 新中医, 2024, 56(14): 178-183.

[18]

郑新宝, 陈佳玉, 杨爱萍, 等. 双丹明目胶囊对糖尿病视网膜病变大鼠视网膜的保护作用及其机制[J]. 眼科新进展, 2023, 43(4): 279-283.

[19]

马静, 刘和忠, 孟希, 等. 明目地黄丸联合羟苯磺酸钙治疗肝肾阴虚型老年糖尿病视网膜病变的临床研究[J]. 糖尿病新世界, 2024, 27(13): 175-178.

[20]

顾勤萍, 沈丽丽, 沈旭良. 芪地活血明目汤治疗非增殖期糖尿病视网膜病变的疗效观察及对新生血管的影响[J]. 中国中医药科技, 2023, 30(2): 264-266.

[21]

李君卿, 陶雯璇, 张元坤, 等. 祛瘀明目汤联合羟苯磺酸钙对糖尿病视网膜病变患者疗效及血清VEGF和FGF21水平影响[J]. 生命科学仪器, 2023, 21(6): 201-204.

[22]

赵永旺, 符超君, 颜家朝, 等. 双丹明目胶囊对糖尿病视网膜病变大鼠血液流变学和视网膜微血管的影响[J]. 眼科新进展, 2022, 42(5): 342-346.

[23]

边云, 田风胜. 贞莲明目胶囊治疗肝肾阴虚痰瘀湿阻型非增殖期糖尿病视网膜病变的临床研究[J]. 中医临床研究, 2023, 15(31): 51-55.

[24]

胡春燕. 止血散瘀明目汤与西药联合治疗非增殖期糖尿病视网膜病变的效果分析[J]. 世界复合医学, 2023, 9(9): 36-38, 42.

[25]

高雅婷. 双丹明目胶囊治疗糖尿病视网膜病变研究进展及抗血管内皮生长因子的思考[J]. 中国民间疗法, 2023, 31(13): 121-125.

[26]

王志勇, 戚俊凯, 罗顺利. 明目地黄丸联合玻璃体腔内注射雷珠单抗治疗非增殖期糖尿病视网膜病变伴黄斑水肿临床研究[J]. 新中医, 2023, 55(14): 82-87.

[27]

边云, 田风胜. 贞莲明目胶囊对非增殖期糖尿病视网膜病变白细胞介素-6、白细胞介素-1β、肿瘤坏死因子-α等炎症因子的影响[J]. 中医临床研究, 2023, 15(28): 37-41.

[28]

赵杰琼, 郝盈, 张自峰. 和血明目片联合全视网膜光凝术治疗非增殖型糖尿病视网膜病变的效果及对视觉能力的影响[J]. 临床医学研究与实践, 2023, 8(23): 125-128.

[29]

张静, 李贵富. 玻璃体注药联合石斛明目丸口服对增殖型糖尿病视网膜病变患者手术治疗效果及视力的影响研究[J]. 山西医药杂志, 2022, 51(10): 1088-1091.

[30]

冯海霞, 罗丹, 高瞻, 等. 养阴活血明目方治疗重度非增殖性糖尿病视网膜病变(阴虚燥热证)的临床观察[J]. 中国中医急症, 2022, 31(2): 336-338.

[31]

冯晓桃, 黄小琪, 段慧明, 等. 基于内质网应激与自噬及其交互作用研究蒲黄总黄酮对游离脂肪酸诱导损伤胰岛β细胞影响的机制[Z]. 广西中医药大学. 2022.

[32]

魏方勇, 王佳, 刘庆泽, 等. 基于HIF-1α/VEGF信号通路探讨丹参提取物对糖尿病视网膜病变大鼠模型的影响[J]. 中华中医药学刊, 2023, 41(10): 187-191, 后插34-后插36.

[33]

LI Y, DENG X, ZHUANG W L, et al. Tanshinone IIA down-regulates-transforming growth factor beta 1 to relieve renal tubular epithelial cell inflammation and pyroptosis caused by high glucose[J]. Bioengineered, 2022, 13(5): 12224-12236.

2026年第44卷第8期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.13193/j.issn.1673-7717.2026.08.027

首发时间：2026-10-20
出版时间：2026-08-10

补充材料

相关文章

文章信息

作者

出版历史

基金

国家重点研发计划项目(2019YFC1710201)

河北省卫生健康委科研基金项目(20191053)

河北省邢台市科学技术局项目(2023ZC174)

作者信息

河北省眼科医院，河北眼科研究所，河北　邢台　054001

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zhzyyxk/CN/10.13193/j.issn.1673-7717.2026.08.027

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT